Page 377, fig. 1 , the following text, which previously read:
Box 8: "Full-text excluded (n = 211)" should read "Fulltext excluded (n = 212)"
"Duplicates: 91" should read "Duplicates 92" Box 9: "Full-text articles assessed for eligibility (n = 29)" should read "Full-text articles assessed for eligibility (n = 28)" Box 10: "Studies included in qualitative synthesis (n = 29)" should read "Studies included in qualitative synthesis (n = 28)"
Box 11: 'Studies included in quantitative synthesis (n = 29)" should read 'Studies included in quantitative synthesis (n = 28)" "G-CSF biosimilars:13 RCTs + 10 Cohort studies" should read "G-CSF biosimilars:13 RCTs + 9 Cohort studies"
A corrected version of Fig. 1 is shown below:
Page 379, Page 381, section 3.2.2, paragraph 3, line 10: The sentence, which previously read "In addition, five cohort studies [40, 41, 45, 48, 49] compared the incidence of FN in cycle 1 in cancer patients treated with filgrastim biosimilars (860 patients) and filgrastim (6970 patients)."
should read "In addition, four cohort studies [40, 41, 48, 49] compared the incidence of FN in cycle 1 in cancer patients treated with filgrastim biosimilars (557 patients) and filgrastim (6755 patients)." Page 382, Table 3 , 'FN incidence in cycle 1 (3 wk)' section, 'Cohort study' study type: the values in the 'Cancer type/Breast cancer' row and the 'Total' row have been corrected. A corrected version of the table is shown below with the corrected text shown in bold. ' that previously read "5 [20, 21, 25, 27, 28]" should read "4 [20, 21, 27, 28] " the text in column 'patient' that previously read "7830" should read "7312" Electronic Supplementary Material, page 9, reference #25: this reference should be deleted Fig. 3 Meta-analysis of G-CSF biosimilar drugs vs G-CSF drugs. ADE at least one adverse drug event, ANC absolute neutrophil count, CI confidence interval, DSN duration of severe (grade 4) neutropenia, ES effect size, F biosimilars filgrastim biosimilars, FN febrile neutropenia, G-CSF granulocyte colony-stimulating factors, NHL non-Hodgkin's lymphoma, NSCLC nonsquamous non-small-cell lung cancer, P biosimilars pegfilgrastim biosimilars, RCT randomized controlled trial, RR risk ratio, WMD weighted mean differences
